{"id":"https://openalex.org/W2254255083","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3028","title":"Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen","display_name":"Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2254255083","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3028","mag":"2254255083"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.3028","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3028","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.3028","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"J. Baselga","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012974257","display_name":"Federico Rojo","orcid":"https://orcid.org/0000-0001-9989-0290","observed_orcids":["https://orcid.org/0000-0001-9989-0290"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"F. Rojo","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026692589","display_name":"Herlinde Dumez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"H. Dumez","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000961519","display_name":"Alain C. Mita","orcid":"https://orcid.org/0009-0009-3260-4793","observed_orcids":["https://orcid.org/0009-0009-3260-4793","https://orcid.org/0000-0002-5387-0160"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"A. Mita","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045286901","display_name":"Chris H.M. Takimoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"C. H. Takimoto","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015190461","display_name":"Josep M. Tabernero","orcid":"https://orcid.org/0000-0002-2495-8139","observed_orcids":["https://orcid.org/0000-0002-2495-8139"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"J. Tabernero","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052704302","display_name":"Clifford DiLea","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"C. Dilea","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080488458","display_name":"Kathryn Parker","orcid":"https://orcid.org/0009-0008-7675-5262","observed_orcids":["https://orcid.org/0009-0008-7675-5262"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"K. Parker","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010851480","display_name":"Margaret Han Dugan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"M. Dugan","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111734683","display_name":"A.T. van Oosterom","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4210143510","display_name":"Novartis (Spain)","ror":"https://ror.org/042e6sa59","country_code":"ES","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210143510"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","ES"],"is_corresponding":false,"raw_author_name":"A. T. van Oosterom","raw_affiliation_strings":["Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron Univ Hosp, Barcelona, Spain; Hosp Vall d\u2019Hebron, Barcelona, Spain; Univ Hosp Gasthuisberg, KU-Leuven, Belgium; IDD/Cancer Therapy and Research Ctr, San Antonio, TX; Novartis Pharmaceuticals Corp., East Hanover, NJ","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4210143510","https://openalex.org/I99464096"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"3028","last_page":"3028"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.5985999703407288,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.5985999703407288,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.2087000012397766,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.057999998331069946,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aee788","display_name":"AEE788","score":0.9869999885559082},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.8830000162124634},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6010000109672546},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.9950000047683716},{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.9980000257492065},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9580000042915344},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9890000224113464},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.45100000500679016},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7450000047683716},{"id":"https://openalex.org/keywords/egfr-signaling-inhibition","display_name":"EGFR signaling inhibition","score":0.7360000014305115},{"id":"https://openalex.org/keywords/mapk-inhibition","display_name":"MAPK inhibition","score":0.6370000243186951},{"id":"https://openalex.org/keywords/ki-67","display_name":"Ki-67","score":0.9800000190734863},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.6909999847412109},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.460999995470047},{"id":"https://openalex.org/keywords/concentration-response-relationship","display_name":"concentration-dependent effects","score":0.6919999718666077},{"id":"https://openalex.org/keywords/emax-model","display_name":"Emax model","score":0.6119999885559082},{"id":"https://openalex.org/keywords/ic50","display_name":"IC50","score":0.7570000290870667}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8173747062683105},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6645451784133911},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.639888346195221},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5838437080383301},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5268306136131287},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4867849051952362},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.47887131571769714},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.43053731322288513},{"id":"https://openalex.org/C101544691","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor tyrosine kinase","level":3,"score":0.4243167042732239},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41217750310897827},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.36196738481521606},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.22946658730506897},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.12664133310317993},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11737754940986633},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.08750265836715698}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.3028","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3028","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.3028","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2244049209","https://openalex.org/W2273382978","https://openalex.org/W2168699626","https://openalex.org/W2595327899","https://openalex.org/W3021671711","https://openalex.org/W2591287814","https://openalex.org/W2240276766","https://openalex.org/W2140452388","https://openalex.org/W2278662399","https://openalex.org/W2247544749"],"abstract_inverted_index":{"3028":[0],"Background:":[1],"AEE788":[2,51,88,167],"is":[3,28,222],"an":[4],"orally":[5],"active,":[6],"small-molecule,":[7],"multitargeted":[8],"kinase":[9],"inhibitor":[10],"with":[11,46,159,175,203,224,256],"potent":[12],"inhibitory":[13],"activity":[14],"against":[15],"multiple":[16],"tyrosine":[17],"kinases,":[18],"including":[19],"EGFR,":[20],"HER2,":[21],"and":[22,40,65,89,106,111,130,134,137,146,168,173,177,192,215,234,251,263],"VEGFR2.":[23],"This":[24],"phase":[25],"I":[26],"study":[27],"being":[29],"conducted":[30],"to":[31,71,117,149],"assess":[32],"its":[33],"safety,":[34],"PK,":[35,261],"PD,":[36,262],"maximum":[37],"tolerated":[38],"dose,":[39],"optimal":[41],"biologic":[42],"dose":[43,176],"in":[44,68,102,123,190,197,213],"pts":[45,156],"advanced":[47],"solid":[48],"tumors.":[49],"Methods:":[50],"was":[52,201,217],"given":[53],"PO":[54],"at":[55,237],"25,":[56],"50,":[57],"100,":[58],"150,":[59],"225,":[60],"300,":[61],"400,":[62],"450,":[63],"500,":[64],"550":[66],"mg/day":[67],"28-day":[69],"cycles":[70,164],"3\u20136":[72],"pt":[73],"cohorts.":[74],"24-hr":[75],"PK":[76,85],"profiles":[77],"were":[78,93,100,115,127,139,152,157,181,249],"performed":[79],"on":[80],"days":[81],"1,":[82],"15,":[83],"28.":[84],"parameters":[86],"of":[87,162,210,231,260],"AQM674":[90,169],"(active":[91],"metabolite)":[92],"computed":[94],"by":[95,141],"model-independent":[96],"methods.":[97],"PD":[98,124],"markers":[99,125],"analyzed":[101],"skin":[103],"(SK),":[104],"wound":[105],"tumor":[107],"(TU)":[108],"biopsies":[109],"pre-":[110,133],"post-treatment.":[112,135],"Emax":[113,136,151,200],"models":[114],"used":[116],"characterize":[118],"concentration-effect":[119],"relationships.":[120],"%":[121],"change":[122],"(%dE=100*1-Et/Eo)":[126],"computed,":[128],"Eo":[129],"Et":[131],"are":[132],"IC50":[138,179,253],"estimated":[140,182,252],"non-linear":[142],"least":[143],"squares":[144],"regression,":[145],"doses":[147,239],"corresponding":[148],"80%":[150,199],"computed.":[153],"Results:":[154],"69":[155],"treated":[158],"a":[160,268],"median":[161],"2":[163],"(range":[165],"<1\u201310).":[166],"concentrations":[170],"varied":[171],"widely":[172],"increased":[174],"duration.":[178],"values":[180,254],"for":[183,272],"pEGFR":[184,193],"(42nM),":[185],"pMAPK":[186,195,233],"(38nM),":[187],"Ki67":[188,235],"(7nM)":[189],"SK":[191,214],"(28nM),":[194],"(22nM)":[196],"TU;":[198],"achieved":[202,223],"100\u2013300":[204],"mg/day.":[205,227],"Conclusions:":[206],"A":[207],"dose-dependent":[208],"inhibition":[209,221,230,242],"EGFR":[211,241],"signaling":[212],"TU":[216],"observed;":[218],"profound":[219],"receptor":[220],"\u2265":[225],"300":[226,244],"As":[228],"expected,":[229],"endothelial":[232],"occurs":[236],"higher":[238],"than":[240],"(\u2265":[243],"mg).":[245],"Exposure":[246],"dependent":[247],"effects":[248],"observed":[250],"agree":[255],"preclinical":[257],"data.":[258],"Integration":[259],"clinical":[264,274],"response":[265],"will":[266,278],"suggest":[267],"potentially":[269],"therapeutic":[270],"regimen":[271],"further":[273],"evaluation.":[275],"Model":[276],"development":[277],"continue":[279],"as":[280],"more":[281],"data":[282],"become":[283],"available.":[284],"Author":[285],"Disclosure":[286],"Employment":[287],"or":[288,291],"Leadership":[289],"Consultant":[290],"Advisory":[292],"Role":[293],"Stock":[294],"Ownership":[295],"Honoraria":[296],"Research":[297],"Funding":[298],"Expert":[299],"Testimony":[300],"Other":[301],"Remuneration":[302],"Novartis":[303,319,326],"Aventis,":[304,320],"Bristol-Myers":[305],"Squibb,":[306],"Lilly":[307],"Oncology,":[308,325],"Merck":[309],"KgaA":[310],"(A),":[311],"Novartis,":[312,321],"Pfizer,":[313,322],"Pharma":[314],"Mar,":[315],"Roche,":[316],"Roche":[317,323],"(A)":[318],"ILEX":[324]},"counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}